Form 4: Haemonetics EVP, Chief Technology Officer Anila Lingamneni Reports Stock Transactions

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics, reports the acquisition and disposal of company stock and stock options.

Summary

• Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 17, 2024, Ms. Lingamneni disposed of 349 shares of common stock at a price of $95.73 per share to cover tax obligations related to vesting restricted stock units (RSUs).
• On the same day, she acquired 3,394 shares of common stock in the form of RSUs under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• These RSUs vest in three equal annual installments starting on the first anniversary of the grant date.
• Each RSU represents the right to receive one share of Haemonetics common stock when vested.
• Also on May 17, 2024, Ms. Lingamneni acquired 7,461 non-qualified stock options with an exercise price of $95.73, vesting in annual increments of 25% beginning on the first anniversary of the grant date.
• Following these transactions, Ms. Lingamneni beneficially owns 14,685 shares of common stock and 7,461 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing and does not inherently convey positive or negative sentiment. It simply reports transactions.

Positives

• The acquisition of RSUs and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to align the interests of management with those of shareholders.
• The vesting schedules for the RSUs (three equal annual installments) and stock options (25% annually) are typical in the industry.
• Comparing the size of the RSU and option grants to those of executives at similar-sized medical device companies (e.g., Teleflex, Medtronic) could provide further context.

Stakeholder Impact

• Shareholders may be interested in the transactions of company executives as an indicator of management's confidence in the company.

Key Dates